StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
23
Publishing Date
2023 - 12 - 12
19
2023 - 12 - 11
25
2023 - 10 - 24
18
2023 - 10 - 23
18
2023 - 09 - 26
18
2023 - 09 - 11
19
2023 - 06 - 05
27
2023 - 05 - 25
27
2023 - 04 - 26
19
2023 - 02 - 13
18
2022 - 12 - 12
18
2022 - 12 - 08
21
2022 - 10 - 26
18
2022 - 09 - 08
18
2022 - 06 - 22
19
2022 - 06 - 06
21
2022 - 05 - 31
18
2022 - 05 - 26
23
2022 - 05 - 23
25
2022 - 03 - 15
20
2022 - 03 - 14
20
2022 - 03 - 01
22
2022 - 02 - 28
22
2022 - 01 - 24
19
2022 - 01 - 18
20
2022 - 01 - 04
18
2021 - 12 - 16
18
2021 - 12 - 14
22
2021 - 12 - 13
37
2021 - 12 - 09
25
2021 - 12 - 06
33
2021 - 12 - 01
20
2021 - 11 - 30
18
2021 - 11 - 15
24
2021 - 11 - 08
22
2021 - 11 - 03
20
2021 - 10 - 28
21
2021 - 10 - 27
18
2021 - 10 - 25
21
2021 - 10 - 20
18
2021 - 10 - 18
18
2021 - 10 - 14
19
2021 - 10 - 13
22
2021 - 10 - 07
22
2021 - 09 - 29
19
2021 - 09 - 13
28
2021 - 09 - 09
19
2021 - 09 - 08
20
2021 - 07 - 27
19
2021 - 07 - 15
18
2021 - 07 - 06
19
2021 - 06 - 28
26
2021 - 06 - 24
18
2021 - 06 - 23
24
2021 - 06 - 11
18
2021 - 06 - 08
18
2021 - 06 - 07
30
2021 - 05 - 12
18
2021 - 04 - 12
21
2021 - 03 - 18
19
Sector
Commercial services
1
Health technology
16
Manufacturing
2
Retail trade
1
Tags
Als
1
Approval
1
Asco
7
Bavencio
1
Biosimilar
1
Biotech-bay
1
Bt7480
1
Can-2409
1
Cancer
3
Cell carcinoma
1
China
1
Clinical-trials-phase-i
1
Clinical-trials-phase-ii
7
Clinical-trials-phase-iii
2
Control
1
Covid
1
Covid-19
1
Cx-904
1
Disease
1
Europe
1
Expansion
1
Genetown
1
Grant
1
Grocers
1
Hb-200
1
Keytruda
1
Multiple sclerosis
1
N/a
7
Ongoing
1
Osmic-021
1
Ovarian cancer
1
Pharm-country
2
Pharma
1
Phase 1
6
Phase 2
1
Phase 3
2
Positive
1
Potential
1
Presentation
2
Probody
1
Renal
1
Research
1
Response
1
Results
2
Sclerosis
1
Set
1
Success
1
Therapeutics
6
Tpst-1120
1
Treatment
2
Trial
15
Trials
3
Urothelial carcinoma
2
Wp1122
1
Entities
4d pharma plc - adr
1
Amylyx pharmaceuticals, inc.
1
Aravive, inc.
1
Ascendis pharma a/s
1
Axcella health inc.
1
Bicycle therapeutics plc
1
Candel therapeutics inc
1
Caredx, inc.
1
Centogene n.v.
1
Cytomx therapeutics, inc.
1
Effector therapeutics inc
1
Eli lilly and company
1
Exelixis, inc.
1
Hookipa pharma inc.
1
Johnson & johnson
1
Moleculin biotech, inc.
1
Morphosys ag
1
Natural grocers by vitamin cottage, inc.
1
Oncternal therapeutics, inc.
1
Sanofi
1
Sellas life sciences group, inc.
1
Sierra oncology, inc.
1
Takeda pharmaceutical company limited
1
Tempest therapeutics inc
1
Tg therapeutics, inc.
1
Upstart holdings inc
1
Xencor, inc.
1
Symbols
AMLX
1
ARAV
1
ASND
1
AXLA
1
BCYC
1
CADL
1
CDNA
1
CNTG
1
CTMX
1
EFTR
1
EXEL
1
HOOK
1
JNJ
1
LBPS
1
LLY
1
MBRX
1
MOR
1
MPSYF
1
NGVC
1
ONCT
1
SLS
1
SNY
1
SNYNF
1
SRRA
1
TAK
1
TGTX
1
TPST
1
UPST
1
XNCR
1
Exchanges
Nasdaq
21
Nyse
3
Crawled Date
2022 - 05 - 27
7
2022 - 05 - 26
16
Crawled Time
00:00
6
08:00
1
09:00
1
10:00
1
12:00
2
12:20
1
13:00
1
13:20
2
14:00
2
14:20
1
15:00
1
17:00
1
21:00
1
22:00
1
23:00
1
Source
www.4dpharmaplc.com
1
www.biospace.com
16
www.clarivate.com
1
www.globenewswire.com
2
www.prnewswire.com
3
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
publishing date :
2022 - 05 - 26
save search
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published:
2022-05-26
(Crawled : 09:00)
- 4dpharmaplc.com
LBPS
|
$1.65
-0.61%
|
Manufacturing
|
-50.0%
|
O:
1.82%
H:
0.99%
C:
0.3%
bavencio
pharma
trial
urothelial carcinoma
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Published:
2022-05-26
(Crawled : 00:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-11.89%
|
O:
-0.17%
H:
0.0%
C:
0.0%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
29.28%
|
O:
0.11%
H:
0.0%
C:
0.0%
osmic-021
trial
asco
results
cancer
urothelial carcinoma
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
Published:
2022-05-26
(Crawled : 00:00)
- biospace.com/
SRRA
|
$54.99
0.04%
0.0%
|
Health Technology
|
0.53%
|
O:
0.05%
H:
0.0%
C:
0.0%
presentation
phase 3
Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)
Published:
2022-05-26
(Crawled : 00:00)
- biospace.com/
ARAV
|
$0.0401
4.74%
4M
|
Health Technology
|
-95.75%
|
O:
0.0%
H:
0.0%
C:
0.0%
renal
asco
potential
cell carcinoma
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting
Published:
2022-05-26
(Crawled : 00:00)
- biospace.com/
EFTR
|
$1.99
3.5%
140K
|
|
4.74%
|
O:
-1.05%
H:
0.0%
C:
0.0%
ongoing
expansion
trial
therapeutics
asco
phase 1
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
Published:
2022-05-26
(Crawled : 00:00)
- biospace.com/
HOOK
|
$0.7633
-5.75%
-6.11%
490K
|
Health Technology
|
-50.33%
|
O:
1.96%
H:
0.0%
C:
0.0%
hb-200
treatment
asco
phase 1
phase 2
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
Published:
2022-05-26
(Crawled : 00:00)
- biospace.com/
ONCT
P
|
$8.71
0.23%
0.23%
4K
|
Health Technology
|
1043.04%
|
O:
-1.65%
H:
0.0%
C:
0.0%
therapeutics
asco
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
Published:
2022-05-26
(Crawled : 23:00)
- biospace.com/
BCYC
|
$21.87
-0.27%
-0.27%
470K
|
Health Technology
|
39.42%
|
O:
-0.89%
H:
4.04%
C:
-3.78%
bt7480
trials
trial
therapeutics
asco
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
Published:
2022-05-26
(Crawled : 22:00)
- globenewswire.com
CADL
|
$5.425
-7.9%
-8.57%
840K
|
|
55.82%
|
O:
-1.6%
H:
14.27%
C:
14.27%
can-2409
disease
control
trial
therapeutics
response
cancer
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting
Published:
2022-05-26
(Crawled : 21:00)
- globenewswire.com
TPST
|
$3.26
-2.69%
-2.76%
350K
|
Manufacturing
|
-15.28%
|
O:
-15.8%
H:
1.23%
C:
-12.92%
tpst-1120
trial
asco
positive
phase 1
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
Published:
2022-05-26
(Crawled : 17:00)
- biospace.com/
AMLX
|
$1.99
-1.0%
-1.01%
1.7M
|
|
-76.55%
|
O:
-0.58%
H:
0.0%
C:
-7.98%
als
trial
presentation
results
How a “fail fast” approach can set clinical trials up for success
Published:
2022-05-26
(Crawled : 15:00)
- clarivate.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-20.07%
|
O:
-0.31%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
144.54%
|
O:
-0.41%
H:
0.0%
C:
0.0%
trials
success
set
trial
4 Biotechs Show Off Pipeline Advancements: Dante, Arrowhead, Forma & Nurix
Published:
2022-05-26
(Crawled : 14:20)
- biospace.com/
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-17.14%
|
O:
-0.13%
H:
0.0%
C:
0.0%
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Upstart Holdings, Inc. (UPST) Investors with $500,000+ Losses to Contact Firm's Attorneys, Expanded Class Period in Securities Fraud Class Action
Published:
2022-05-26
(Crawled : 14:00)
- prnewswire.com
UPST
4
|
$22.42
-0.53%
-0.54%
3M
|
|
-44.55%
|
O:
-3.83%
H:
0.0%
C:
0.0%
trial
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed
Published:
2022-05-26
(Crawled : 14:00)
- prnewswire.com
CDNA
|
$8.28
5.48%
5.19%
2M
|
Health Technology
|
-67.11%
|
O:
-0.04%
H:
0.0%
C:
0.0%
trial
Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Published:
2022-05-26
(Crawled : 13:20)
- biospace.com/
MBRX
|
$4.28
-2.41%
10K
|
Health Technology
|
217.04%
|
O:
2.22%
H:
5.8%
C:
4.35%
wp1122
covid-19
treatment
trial
phase 1
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors- EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic -
Published:
2022-05-26
(Crawled : 13:20)
- biospace.com/
CTMX
|
$1.765
-5.11%
-5.38%
590K
|
Health Technology
|
15.53%
|
O:
-4.35%
H:
2.6%
C:
1.95%
cx-904
probody
therapeutics
phase 1
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
Published:
2022-05-26
(Crawled : 13:00)
- biospace.com/
SLS
|
$1.405
3.31%
3.2%
560K
|
Health Technology
|
-54.22%
|
O:
6.49%
H:
0.0%
C:
-11.59%
keytruda
trial
cancer
phase 1
ovarian cancer
Global Roundup: Iceland's Alvotech Hits Mark with Biosimilar to Janssen's Ste...
Published:
2022-05-26
(Crawled : 12:20)
- biospace.com/
CNTG
|
$0.4801
0.14%
17K
|
Commercial Services
|
-82.15%
|
O:
-0.37%
H:
3.73%
C:
0.75%
ASND
|
$142.12
0.44%
0.44%
300K
|
Health Technology
|
54.43%
|
O:
-2.44%
H:
0.0%
C:
0.0%
biosimilar
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
Published:
2022-05-26
(Crawled : 12:00)
- biospace.com/
TGTX
|
$13.825
-1.25%
-1.27%
3.1M
|
Health Technology
|
179.19%
|
O:
0.81%
H:
5.31%
C:
1.2%
trials
therapeutics
sclerosis
phase 3
multiple sclerosis
← Previous
1
2
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.